Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Mylan Suffers Several Setbacks: What's in Store in 2H18?
by Zacks Equity Research
Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.
AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma
by Zacks Equity Research
AbbVie's (ABBV) cancer drug Imbruvica gets FDA approval for use in combination with Roche's Rituxan for Waldenstrom's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.
5 Reasons Why You Should Add Lilly Stock to Your Portfolio
by Zacks Equity Research
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco
by Zacks Equity Research
The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.
Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic
by Zacks Equity Research
Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.
Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen
by Zacks Equity Research
Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.
Regeneron, Teva Announce Positive Data on Osteoarthritis Drug
by Zacks Equity Research
Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
Invest Like Buffett & Berkshire With These Top Stock Picks
by Benjamin Rains
Warren Buffett has for years been looked at as an investment icon, while maintaining a relatively simple mantra. Buffett and Berkshire Hathaway (BRK.B) have long tried to invest in companies that both the Oracle of Omaha and the conglomerate understand. This sounds easy enough, but what are some of Buffett's most recent investments?
Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings
by Zacks Equity Research
Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.
BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.
Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2
by Zacks Equity Research
Momenta (MNTA) reports wider-than-expected Q2 loss. Sales miss estimates too. The focus now is on the outcome of the ongoing strategic review including a possible sale of the biosimilar business.
TEVA vs. TLGT: Which Stock Is the Better Value Option?
by Zacks Equity Research
TEVA vs. TLGT: Which Stock Is the Better Value Option?
Mylan (MYL) Q2 Earnings: Is a Disappointment in the Cards?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars along with other updates from Mylan's (MYL) pipeline, when it reports Q2 results (scheduled for Aug 8).
Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down
by Zacks Equity Research
Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.
Company News For Aug 3, 2018
by Zacks Equity Research
Companies in the news are: CI, TSLA, TEVA and REGN
Teva (TEVA) Beats on Q2 Earnings, Misses Sales, Shares Dip
by Zacks Equity Research
Teva's (TEVA) second-quarter earnings beat estimates but sales miss expectations. Teva maintains its 2018 sales guidance while raising the earnings outlook. Shares dip in pre-market trading
Teva (TEVA) Q2 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1
by Zacks Equity Research
Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.
Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up
by Zacks Equity Research
Amgen (AMGN) impresses with better-than-estimated second-quarter results and raises its outlook for the full year. Shares rise in after-hours trading.
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
4 Warren Buffett Stocks to Buy in Q2 Earnings
by Tirthankar Chakraborty
We highlight four of the Oracle of Omaha's sought-after companies that are likely to report upbeat second-quarter earnings.
Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TEVA) Outperforming Other Medical Stocks This Year?
TEVA or AKRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TEVA vs. AKRX: Which Stock Is the Better Value Option?
Lilly Wins Favorable Ruling From U.S. Court in Alimta Row
by Zacks Equity Research
Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.
Teva to Discontinue a Fremanezumab Study on Cluster Headache
by Zacks Equity Research
Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.